RxDoctor Payments Data

Lawrence Santi

Foot Surgery · Brooklyn, NYNPI 1982676581

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $15,203 of the $24,817 with a category attached, or 61.3%. Organogenesis Inc. accounts for 75.2% of it on its own, with 31 other manufacturers making up the rest. Among foot surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$24,817in general payments, 2019–2025

Across 144 payments — averaging $172.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$19K
  • Heron Therapeutics, Inc.$2K
  • Abbott$571
  • Smith+Nephew$451
  • Bioventus LLC$377
  • Paratek Pharmaceuticals, Inc.$368
  • plus $3K from 26 others

What the payments were for

  • Consulting fees$3,19913%
  • Speaking & faculty fees$15,20361%
  • Food & beverage$6,38126%
  • Gifts$350%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,817 in reported general payments places this provider in the 95th percentile of 294 foot surgery providers in New York.

See all foot surgery providers in New York

Medicare billing

Part B allowed, 2024
$371,262
Medicare patients
183
Services billed
2,107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Febuxostat22$2,780
Ammonium Lactate51$1,171
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip63$1,167
Ketoconazole26$833
Mupirocin110$639
Doxycycline Hyclate71$445
Clotrimazole15$387
Meloxicam79$230
Clindamycin Hcl11$221
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav16$162
Hydrocortisone11$140
Furosemide18$87

Paid to pharmacies, not to this prescriber.

Other foot surgery in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →